ArticleFrontiers in immunology2025

Efgartigimod for generalized myasthenia gravis in the extreme elderly (≥80 years): a multicenter retrospective real-world study.

Ye Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.